NYRADA INC. (ASX:NYR) 10 Looking Ahead The past year saw Nyrada become a company that doses patients, protects its inventions across key markets, and pursues its science on more than one front. We remain mindful of the risks inherent in clinical development, but the groundwork laid over FY2026 places us in the strongest position in the Company's history. As we move into FY2027, our priorities are clear and our path well defined: • to advance PROTECT-MI toward conclusion and data read-out; • to lodge our IND with the US FDA; and • to further advance our research program to enhance the value of Xolatryp. I extend my sincere thanks to the Nyrada team, our clinical partners, investigators, and advisors, whose dedication has driven this progress. I thank also the Board for its steadfast support. Above all, I thank our CDI holders. We have achieved a great deal this year and, with Xolatryp in the clinic, we are only getting started. Sincerely, James Bonnar Managing Director and Chief Executive Officer Nyrada Inc.
RkJQdWJsaXNoZXIy MjE2NDg3